In conclusion, the ability of anti-RANKL therapy to restore muscle function has profound implications for DMD patients as it offers the possibility of improving skeletal muscle function without the steroid-related skeletal side effects. This evidence concerns the gene TNFSF11 and Duchenne muscular dystrophy.